Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
NCT01101581 · Gilead Sciences · PHASE1/PHASE2 · withdrawn · last registry update 2021-08-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “No subjects enrolled” | – | Registry record, Gilead Sciences |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MS4A1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-06-08Phase 3 first posted: Genmab, Epcoritamab + Rituximab (NCT05409066)
- 2022-03-28Results posted on the registry: Janssen Research & Development, LLC, Ibrutinib + Venetoclax (NCT03462719)
- 2022-03-07Phase 3 first posted: Hoffmann-La Roche, Ocrelizumab (NCT05269004)
- 2022-02-10Phase 3 first posted: Hoffmann-La Roche, Ocrelizumab IV + Ocrelizumab SC (NCT05232825)
- 2022-01-19Phase 3 first posted: German CLL Study Group, Obinutuzumab + Venetoclax (NCT05197192)
- 2021-12-29Phase 3 first posted: Hoffmann-La Roche, Mosunetuzumab + Polatuzumab vedotin (NCT05171647)
- 2021-11-17Phase 3 first posted: Hoffmann-La Roche, Ocrelizumab + Fingolimod (NCT05123703)
- 2021-10-29Phase 3 first posted: BeOne Medicines, Zanubrutinib + Rituximab (NCT05100862)
- 2021-09-27Phase 3 first posted: AstraZeneca, Acalabrutinib + Venetoclax (NCT05057494)
- 2021-09-27Phase 3 first posted: Fondazione Italiana Linfomi - ETS, Immunochemotherapy regimen: Rituximab-bendamustine (Arm A) + Immunochemotherapy regimen: Rituximab-bendamustine (Arm B) (NCT05058404)
- 2021-09-16Phase 3 first posted: Heidelberg University, Standard + Experimental (NCT05045664)
- 2021-07-15Phase 3 first posted: Hoffmann-La Roche, Obinutuzumab + Placebo (NCT04963296)
- 2021-01-15Phase 3 first posted: Hoffmann-La Roche, Mosunetuzumab + Lenalidomide (NCT04712097)
- 2021-01-08Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Obinutuzumab administration + Administration of Methylprednisolone + Prednisone + Mycophenolate mofetil (NCT04702256)
- 2020-12-30Phase 3 first posted: Copenhagen University Hospital, Rigshospitalet, Rituximab + Ocrelizumab (NCT04688788)
- 2020-11-16Phase 3 first posted: Hoffmann-La Roche, Obinutuzumab + Tacrolimus (NCT04629248)
- 2020-11-13Phase 3 first posted: Genmab, Epcoritamab + Investigator's Choice Chemotherapy (NCT04628494)
- 2020-10-29Phase 3 first posted: German CLL Study Group, Ibrutinib + Venetoclax (NCT04608318)
- 2020-10-08Phase 3 first posted: Haukeland University Hospital, Rituximab + Ocrelizumab (NCT04578639)
- 2020-09-16Phase 3 first posted: Hoffmann-La Roche, Ocrelizumab + Ocrelizumab (NCT04548999)
- 2020-09-10Phase 3 first posted: Hoffmann-La Roche, Ocrelizumab + Ocrelizumab (NCT04544436)
- 2020-09-10Phase 3 first posted: Hoffmann-La Roche, Fenebrutinib + Ocrelizumab (NCT04544449)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision